Article Versions Notes

Kittle WM, Reeves MA, Fulkerson AE, Hamorsky KT, Morris DA, Kitterman KT, Merchant ML, Matoba N. Preclinical Long-Term Stability and Forced Degradation Assessment of EPICERTIN, a Mucosal Healing Biotherapeutic for Inflammatory Bowel Disease. Pharmaceutics. 2025; 17(2):259. https://doi.org/10.3390/pharmaceutics17020259

Kittle, Wendy M., Micaela A. Reeves, Ashley E. Fulkerson, Krystal T. Hamorsky, David A. Morris, Kathleen T. Kitterman, Michael L. Merchant, and Nobuyuki Matoba. 2025. "Preclinical Long-Term Stability and Forced Degradation Assessment of EPICERTIN, a Mucosal Healing Biotherapeutic for Inflammatory Bowel Disease" Pharmaceutics 17, no. 2: 259. https://doi.org/10.3390/pharmaceutics17020259

Kittle, W. M., Reeves, M. A., Fulkerson, A. E., Hamorsky, K. T., Morris, D. A., Kitterman, K. T., Merchant, M. L., & Matoba, N. (2025). Preclinical Long-Term Stability and Forced Degradation Assessment of EPICERTIN, a Mucosal Healing Biotherapeutic for Inflammatory Bowel Disease. Pharmaceutics, 17(2), 259. https://doi.org/10.3390/pharmaceutics17020259